Brief: Nkarta Announces Updated Clinical Data On Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 For Patients With Relapsed Or Refractory Non-Hodgkin Lymphoma

Nkarta

05/12/2022 12:27

Dec 5 (Reuters) - Nkarta Inc  NKTX.O :
    * NKARTA ANNOUNCES UPDATED CLINICAL DATA ON ANTI-CD19
ALLOGENEIC
CAR-NK CELL THERAPY NKX019 FOR PATIENTS WITH RELAPSED OR
REFRACTORY NON-HODGKIN LYMPHOMA
    * NKARTA INC - 7 OF 10 PATIENTS TREATED WITH NKX019
MONOTHERAPY AT
1 BILLION AND 1.5 BILLION CAR NK CELLS PER DOSE ACHIEVED
COMPLETE RESPONSE
    * NKARTA INC - 5 CRS ACHIEVED ACROSS ALL DOSE LEVELS AFTER A
SINGLE CYCLE (3 WEEKLY DOSES) OF NKX019 MONOTHERAPY
    * NKARTA INC - 3 PARTIAL RESPONSES DEEPENED TO CR WITH
ADDITIONAL
CYCLES
    * NKARTA INC - PATIENTS WITH CR OBSERVED ACROSS MULTIPLE NHL
HISTOLOGIES, INCLUDING LBCL
    * NKARTA INC - PLANS TO PROVIDE UPDATES FROM NKX019 PROGRAM,
INCLUDING DATA FROM DOSE EXPANSION COHORTS, IN 2023

Source text for Eikon:  ID:nGNXb7hc4s 
Further company coverage:  NKTX.O